Table 5.
Normalized mRNA Levels in MACS-Sorted ALP+ (Osteoblastic) Cells, CD3+ Cells (T Cells), and CD19+ Cells (B Cells)
| Group A (−T, −E) | Group B (−T, +E) | Group C (+T, −E) | Group D (+T, +E) | E effect | T effect | |
| ALP+ cells | ||||||
| OPG* | 1.72 (0.38, 4.10) | 0.26 (0.17, 5.43) | 2.08 (0.15, 3.04) | 0.80 (0.46, 1.45) | 0.371 | 0.780 |
| TRAIL* | 0.73 (0.44, 1.39) | 0.64 (0.22, 1.07) | 0.45 (0.22, 0.94) | 0.93 (0.25, 1.22) | 0.475 | 0.643 |
| IF30* | 0.58 (0.40, 0.96) | 0.44 (0.24, 1.52) | 0.50 (0.26, 0.80) | 0.63 (0.29, 1.47) | 0.484 | 0.351 |
| TNFαP6* | 1.21 (0.92, 1.71) | 0.94 (0.74, 4.31) | 1.86 (0.62, 2.36) | 0.98 (0.63, 1.10) | 0.570 | 0.496 |
| CD3+ cells | ||||||
| TNFα | 0.87 (0.69, 1.37) | 1.12 (0.81, 1.25) | 0.87 (0.69, 1.34) | 1.02 (0.79, 1.14) | 0.721 | 0.932 |
| IFNγ * | 0.84 (0.38, 1.50) | 0.80 (0.39, 1.22) | 1.04 (0.67, 1.40) | 0.97 (0.62, 1.40) | 0.602 | 0.315 |
| CD14+ cells | ||||||
| TNFα * | 0.96 (0.64, 1.33) | 0.99 (0.86, 1.24) | 0.86 (0.80, 1.16) | 0.95 (0.84, 1.21) | 0.263 | 0.784 |
| IL-1α * | 1.13 (0.35, 1.53) | 0.88 (0.42, 1.60) | 0.67 (0.41, 1.17) | 0.84 (0.39, 1.39) | 0.641 | 0.415 |
| IL-1β * | 0.82 (0.50, 1.29) | 0.71 (0.50, 1.15) | 0.78 (0.63, 0.98) | 0.71 (0.40, 1.29) | 0.885 | 0.932 |
| IL-1ra* | 0.98 (0.65, 1.27) | 1.08 (0.73, 1.50) | 1.08 (0.72, 1.25) | 0.87 (0.70, 1.25) | 0.677 | 0.516 |
| IFNγ * | 0.84 (0.48, 2.41) | 0.63 (0.28, 1.12) | 0.80 (0.24, 1.45) | 0.79 (0.36, 1.38) | 0.267 | 0.361 |
| TNFαP6* | 0.65 (0.37, 1.23) | 1.37 (1.07, 3.04) | 0.73 (0.45, 1.29) | 0.82 (0.51, 1.59) | 0.059 | 0.285 |
Last two columns indicate the p values for E and T effects using the two-factor ANOVA model described in the Materials and Methods section. Data are median (IQR).
* Log2 was used in models.